DHODH-IN-21

®

MedChemExpress

Cat. No.:	HY-149030	
CAS No.:	2450341-39-4	
Molecular Formula:	C ₂₀ H ₁₉ ClF ₄ N ₆ O ₄	_ F
Molecular Weight:	518.85	F
Target:	Dihydroorotate Dehydrogenase	•
Pathway:	Metabolic Enzyme/Protease	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

Product Data Sheet

C۱

O

0

Ν

NH

OH

BIOLOGICAL ACTIV	ТТ				
Description	DHODH-IN-21 (compound 19) value of 1.1 nM. DHODH-IN-21	is an orally active selective dihyd has anticancer activity and can b	Iroorotate dehydrogenase (DHO pe used in studies of acute myeld	DH) inhibitor with an IC ₅₀ bid leukaemia (AML) ^[1] .	
IC ₅₀ & Target	Mouse DHODH 140 nM (IC ₅₀)	Rat DHODH 1580 nM (IC ₅₀)	Dog DHODH 8.5 nM (IC ₅₀)	Monkey DHODH 1.6 nM (IC ₅₀)	
In Vitro	DHODH-IN-21 (compound 19) inhibits the proliferation of MOLM-13 and THP-1 cells with the IC ₅₀ values of 2.0 nM and 5.0 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				
In Vivo	 DHODH-IN-21 (compound 19) (p.o., 10 or 20 mg/kg, everyday, 5 days) inhibits tumor growth in a dose-dependent manner but no effect on body weight in female NSG mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 				
	Animal Model:	Human MOLM-13 AML xenograf	t model in female NSG mice $^{[1]}$		
	Dosage:	10, 20 mg/kg			
	Administration:	Oral administration; everyday;	5 days		
	Result:	Inhibited tumor volume size by	44% and 60% at 10 mg/kg and 2	20 mg/kg respectively.	
	Apimal Model:	Mouro rat[1]			
		Mouse, late			
	Administration:	2 mg/kg i y or 10 mg/kg p o			
	Doculti	The pharmacel/instic paramete	rs of DHODH IN 21 (compound	10)	
	Result.			19)	
		Parameter Mous	se Rat		

CL (mL/min/kg)	11	22
CE (IIIE/IIIII/Kg)	LL	32
V _{dss} (L/kg)	1.3	2.3
t _{1/2} (h)	2.3	2.0
C _{max} (ng/mL)	4047	1713
t _{max} (h)	0.42	1.7
AUC _{0→inf} (h•ng/mL)	16,066	9214
F%	103	167

REFERENCES

[1]. Justin S Cisar, et al. N-Heterocyclic 3-Pyridyl Carboxamide Inhibitors of DHODH for the Treatment of Acute Myelogenous Leukemia. J Med Chem. 2022 Aug 4.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA